Update to NICE guidance for treating Covid-19

The National Institute for Health and Care Excellence (NICE) has republished its guidance TA878 – Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating Covid-19. The recommendation to extend access to treatment for a broader eligible population (people with diabetes, obesity or heart failure, or aged 70 years or over) has been withdrawn. In line with the original recommendation, Nirmatrelvir plus ritonavir (Paxlovid) is only recommended for patients at highest risk of serious illness as defined in Section 5 of TA878. These changes mean that some additional groups that were eligible for treatment are no longer subject to a NICE recommendation. These include:

  • people aged 85 years and over
  • people with end-stage heart failure who have a long-term ventricular assistance device
  • people on the organ transplant waiting list
  • people aged 70 years and over, or who have a BMI of 35 kg/m2 or more, diabetes or heart failure, and are a resident in a care home, or are already hospitalised.
Keep up to date

Sign up to receive our daily news alerts straight to your inbox. Subscribe to our weekly newsletter containing a summary of the week’s news, blog and vote on our poll.

Weekly Newsletter

Daily news updates

Have a discussion

Help keep the conversation going between meetings by creating a forum to hold discussions with your members. It’s an easy way to manage and communicate with members.

Create a network

Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.

Networks can be open to all or available only to a closed group defined by the administrator.

Join or create a network here.